Here, we characterized the antigenic landscape of LSCs and AML bulk cells using mass spectrometry–based immunopeptidomics. We identified AML/LSC-associated (defined as shared among AML bulk cells and ...

Our study addresses the urgent need for treatment strategies for TKI-resistant gastrointestinal stromal tumors (GIST). We have identified a non-TKI compound, OPB-171775, that exhibits significant ...

Endocrine therapy (ET), combined with CDK4/6, mTOR, or PI3K inhibitors, is an effective treatment option for patients with estrogen receptor–positive (ER +)/human epidermal growth factor receptor ...

Insurance giant Cigna accused Bristol Myers Squibb (BMS) of maintaining a monopoly over Pomalyst (pomalidomide), the pharma company’s $2-billion-a-year immunomodulatory drug for multiple myeloma. In a ...

Major Finding: An intraoperative sequencing workflow provides rapid turnaround of comprehensive molecular profiling of central nervous system (CNS) tumors. Concept: Methylation profile and DNA copy ...

Abstract. Background: The 3rd-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), like osimertinib, provide marked clinical benefit for EGFR-mutant non-small cell lung ...

RAS is the most frequently mutated oncogene in human cancer.RAS mutations occur in approximately 260,000 new cancer cases per year in the United States and 3.4 million per year worldwide (). RAS genes ...

Major Finding: Uptake of exogenous lipoproteins through glycosaminoglycans protects cancer cells from ferroptosis.Concept: Lipoproteins inhibit ferroptosis by delivering α-tocopherol, a form of ...

The FDA gave accelerated approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo), a TROP-2 targeting antibody–drug conjugate (ADC), for patients with advanced or metastatic EGFR-mutated ...

In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA + EV-low and -high groups, ...

Tol transgenic mice, tolerant to reporter proteins like luciferase and GFP, can be used to develop improved tumor models for studying metastasis and immunotherapy, avoiding immune rejection issues in ...

29 pts with nine different solid tumors with ATM mut (n=28) or del (n=1) were enrolled. 1 pt was not evaluable for efficacy.Table shows demographics, outcomes, and toxicity. 2 PR (lung and thyroid) ...